BRAF and cutaneous melanoma: The clear similarities between UVR-driven cutaneous melanoma and UVR-associated mucosal melanoma suggest that mucosal melanoma patients with SBS7v2 predominance may benefit from BRAF/MEK inhibitor combinations and from immunotherapies in both the advanced and adjuvant settings.